8-K - BNBX - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):

September 15, 2021

Applied DNA Sciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware<br><br> <br>(State or other jurisdiction<br><br> <br>of incorporation)	001-36745<br><br> <br>(Commission File Number)	59-2262718<br><br> <br>(IRS Employer<br><br> <br>Identification No.)

50 Health Sciences Drive

Stony Brook, New York 11790

(Address of principal executive offices; zip code)

Registrant’s telephone number, including area code: ****

631-240-8800

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
---	---
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
---	---
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
---	---

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	APDN	The<br>Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.07 Submission of Matters to a Vote

of Security Holders.

On September 15, 2021, Applied DNA Sciences, Inc. (the “Company”) held its 2021 annual meeting of stockholders (the “2021 Annual Meeting”). The following proposals were voted on and were approved by the Company’s stockholders at the 2021 Annual Meeting with the stockholders having voted as set forth below:

I.	To elect eight directors to serve until the 2022 annual meeting of stockholders or until their respective successors are duly elected and qualified.
Name	For		Withhold		Broker Non-Votes
---	---	---	---	---	---	---
James A. Hayward		1,571,895		149,891		2,477,667
John Bitzer, III		1,330,637		391,149		2,477,667
Robert B. Catell		1,321,799		399,987		2,477,667
Joseph D. Ceccoli		1,622,020		99,766		2,477,667
Scott Anchin		1,662,903		98,883		2,477,667
Yacov A. Shamash		1,559,583		162,203		2,477,667
Sanford R. Simon		1,489,843		231,943		2,477,667
Elizabeth M. Schmalz Ferguson		1,611,876		109,910		2,477,667
II.	To ratify the approval, filing and effectiveness of the Certificate of Amendment to the Company’s Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on September 16, 2020 to decrease the number of the authorized shares of the Company’s common stock, par value $0.001 per share, to 200,000,000.
---	---
For		Against		Abstain
---	---	---	---	---	---
	3,928,842		259,712		10,899
III.	To ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2021.
---	---
For		Against		Abstain
---	---	---	---	---	---
	4,065,578		108,612		25,263
IV.	To act upon other matters which may properly come before the 2021 Annual Meeting.
---	---
For		Against		Abstain
---	---	---	---	---	---
	3,308,824		652,775		237,854

Each of the foregoing voting results from the 2021 Annual Meeting is final.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 17, 2021	APPLIED DNA SCIENCES, INC.
	By:	/s/ James A. Hayward
	Name:	James A. Hayward
	Title:	Chief Executive Officer